A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose

NCT01663389 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

5

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Bacterial

Interventions

DRUG: GSK1322322 1000 mg containing radioactive 14C-GSK1322322
DRUG: GSK1322322 1200 mg containing radioactive 14C-GSK1322322

Sponsor

GlaxoSmithKline